Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

AskMen.com	Cholesterol & The Prostate A new study suggests that men may be able to lower their risk of getting the most aggressive form of prostate cancer by keeping their cholesterol in a healthy range.
The Motley Fool June 29, 2011 Brian Orelli	Doubling Up in Biotech Lilly hits multiple targets with one drug.
The Motley Fool April 24, 2008 Brian Orelli	Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
Nutrition Action Healthletter October 2001	Read My Lipids How to lower your risk of a heart attack...
The Motley Fool August 27, 2009 Brian Orelli	The List You Have to Be On Good for you if your company's products made the cut in China. This sounds like a growth opportunity for American Oriental Bioengineering and anyone else who can get a place on the list.
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
The Motley Fool September 24, 2010 Brian Orelli	Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year.
Food Processing June 2009 Dave Fusaro	Do They Want Healthier Food or Not? Cheerios may have gone too far, but a `new' FDA should focus on safety and health.
Managed Care July 2005	Cost being equal, consumers prefer older drugs Seven out of 10 consumers would prefer a drug that had been on the market for 10 years or more, compared to a newer drug, even if the copayments were equal. This could be a sign that consumers are more inclined to start using generic medications.
The Motley Fool August 24, 2011 Brian Orelli	Can Roche and Merck Succeed Where Pfizer Failed? CETP inhibitors are lucrative but risky.
AskMen.com June 12, 2012 Dave Golokhov	Low-Carb Diets A new study says carb-cutting diets, like the Atkins one, significantly raise the risk of heart disease.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
The Motley Fool May 10, 2005 Charly Travers	The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice?
Managed Care July 2006	Headlines On Deadline... Initial bids are in and it appears that premium growth will be slowing... Certification guidelines for health care information technology are in the works... New technology doesn't come cheap... etc.
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
The Motley Fool June 6, 2006 Brian Lawler	Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines.
The Motley Fool August 30, 2007 Brian Orelli	Merck Tries to Stop the Flushing The FDA will review the pharma's new cholesterol drug. The biggest worry with getting CORDAPTIVE approved is probably not with its effectiveness, but with safety. Investors, take note.
Chemistry World July 11, 2008 Manisha Lalloo	Side-effects study opens up new drug leads Existing drugs could be used to treat a broader range of diseases, according to scientists in Germany and Denmark, who have predicted drug targets by using side-effects data on medication labels.
Chemistry World March 27, 2013 Eugene Gerden	Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs.
Managed Care November 2005	Plans Change Tactics As Costs Keep Rising For Specialty Drugs With specialty drug costs continually increasing, CuraScript expects to see a significant shift in the percentage of plans exclusively classifying specialty drugs under the medical benefit.
Chemistry World June 26, 2013 Emma Stoye	UN report warns of global rise in legal highs The latest World Drug Report from the United Nations Office on Drugs and Crime says governments around the world are struggling to cope with a growing number of legal party drugs.
Chemistry World August 27, 2015 Phillip Broadwith	Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases.
Managed Care August 2007	Managed Care Outlook Specialty drugs increasingly used to treat chronic conditions.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
Pharmaceutical Executive September 1, 2006 Patrick Clinton	From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs.
The Motley Fool August 25, 2009 Brian Orelli	How to Keep From Losing Your Shirt More side effects for weight-loss drugs -- maybe.
Information Today November 19, 2007	Thomson Healthcare Launches PDRhealth.com as Free Consumer Site The new PDRhealth.com is designed to put critical health information into the hands of consumers.
The Motley Fool November 15, 2011 Brian Orelli	Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck.
Chemistry World May 2009	Column: In the pipeline Derek Lowe considers what we think we know about how drugs work once we've taken them
The Motley Fool February 15, 2006 Selena Maranjian	Juice Your Investing Abilities Some ways to improve your stock picking and some mistakes to avoid.
BusinessWeek April 19, 2004 Catherine Arnst	Cholesterol: How Low Should It Be? New studies say as low as possible, but drugs aren't for everybody
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
Managed Care March 2008	PDP Drug Restrictions Block Comparison Shopping A review of 169 commonly used drugs covered by Medicare Prescription Drug Plans (PDPs) reveals that only 4 of the 10 largest plans by enrollment have all of those 169 drugs on formulary.
Managed Care June 2006 John Carroll	When New Drugs Are Costly, How High to Raise Copays? As some pretty costly, yet very useful, drugs are introduced, will new formulary designs deny access to needy patients?
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
American Family Physician March 1, 2002 Richard S. Safeer	Cholesterol Treatment Guidelines Update In addition to modifying current strategies of risk assessment, the new guidelines stress the importance of an aggressive therapeutic approach in the management of hypercholesterolemia...
The Motley Fool August 6, 2007 Brian Orelli	Cheap Drugs on the Farm The House approves a prescription-drug import provision. Investors should keep an eye on the status of the bill, because laws that hurt the drugmakers' bottom lines will hurt their stock prices as well.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
American Family Physician January 15, 2001	Goals for Lowering Your Cholesterol Why is it important to have a normal cholesterol level?... What does the term "total cholesterol" mean?... Why is LDL called the "bad" cholesterol?... What are normal cholesterol levels?... How can I reduce my LDL and total cholesterol levels?... etc.
Searcher June 2012 Stephanie C. Ardito	The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations.
The Motley Fool August 31, 2007 Brian Orelli	Guidelines to Stop the Wheezing Investors, new asthma guidelines will affect some drug makers. The FDA isn't the only organization that affects how well drugs do in the marketplace.
The Motley Fool March 30, 2009 Brian Orelli	Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore.
Managed Care October 2007	The Formulary Files Retirees stop taking drugs when annual benefit runs out.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
Reason September 2005 Kerry Howley	Locking Up Life-Saving Drugs U.S. prescription laws make us sicker and poorer because the system that puts drugs over the counter is driven by profits and patents.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
Pharmaceutical Executive November 1, 2014 Jill Wechsler	Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
BusinessWeek April 18, 2005	Making Those Pills Safe For Kids Few medicines get tested on children. Dr. Donald Mattison is pushing to change that.
The Motley Fool January 26, 2011 Brian Orelli	Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies.